FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.
https://ift.tt/2IgHyNy
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου